The interactions of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps

• Published in: PLoS pathogens 2023-03, Vol.19 (3), p.e1011167-e1011167
• Main Authors: Wong, Anabelle, Barrero Guevara, Laura Andrea, Goult, Elizabeth, Briga, Michael, Kramer, Sarah C, Kovacevic, Aleksandra, Opatowski, Lulla, Domenech de Cellès, Matthieu
• Format: Article
• Language: English
• Subjects: Analysis; Animal models; Animals; Biology and life sciences; Care and treatment; Coinfection - epidemiology; Comorbidity; Control; Coronaviruses; COVID-19; COVID-19 vaccines; Diagnosis; Disease susceptibility; Disease transmission; Epidemics; Epidemiology; Ferrets; Funding; Hamsters; Health aspects; Health risks; Human populations; Humans; Identification and classification; Influenza; Influenza A; Influenza vaccines; Influenza, Human - epidemiology; Life Sciences; Measles; Medicine and health sciences; Mice; Pathogenic microorganisms; Pathogens; Population studies; Public health; Respiratory diseases; Respiratory syncytial virus; Review; Risk management; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Streptococcus infections; Symmetry; Vaccines; Viral diseases; Viruses
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1011167

Despite the availability of effective vaccines, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suggests that cocirculation with other pathogens and resulting multiepidemics (of, for example, COVID-19 and influenza) may become increasingly frequent. To better forecast and control the risk of such multiepidemics, it is essential to elucidate the potential interactions of SARS-CoV-2 with other pathogens; these interactions, however, remain poorly defined. Here, we aimed to review the current body of evidence about SARS-CoV-2 interactions. Our review is structured in four parts. To study pathogen interactions in a systematic and comprehensive way, we first developed a general framework to capture their major components: sign (either negative for antagonistic interactions or positive for synergistic interactions), strength (i.e., magnitude of the interaction), symmetry (describing whether the interaction depends on the order of infection of interacting pathogens), duration (describing whether the interaction is short-lived or long-lived), and mechanism (e.g., whether interaction modifies susceptibility to infection, transmissibility of infection, or severity of disease). Second, we reviewed the experimental evidence from animal models about SARS-CoV-2 interactions. Of the 14 studies identified, 11 focused on the outcomes of coinfection with nonattenuated influenza A viruses (IAVs), and 3 with other pathogens. The 11 studies on IAV used different designs and animal models (ferrets, hamsters, and mice) but generally demonstrated that coinfection increased disease severity compared with either monoinfection. By contrast, the effect of coinfection on the viral load of either virus was variable and inconsistent across studies. Third, we reviewed the epidemiological evidence about SARS-CoV-2 interactions in human populations. Although numerous studies were identified, only a few were specifically designed to infer interaction, and many were prone to multiple biases, including confounding. Nevertheless, their results suggested that influenza and pneumococcal conjugate vaccinations were associated with a reduced risk of SARS-CoV-2 infection. Finally, fourth, we formulated simple transmission models of SARS-CoV-2 cocirculation with an epidemic viral pathogen or an endemic bacterial pathogen, showing how they can naturally incorporate the proposed framework. More generally, we argue that such models, when designed with an integrative and